Drug Discovery & Development
In 2008, Idenix successfully completed a proof-of-concept study for IDX899, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) to treat HIV, in treatment-naive patients. NNRTIs are important components of effective antiretroviral therapy (ART) combination regimens for the treatment of HIV-1 infected individuals1. In February 2009, Idenix granted GlaxoSmithKline an exclusive license to develop, manufacture and commercialize IDX899.
1 Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents